Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., a step-down wholly-owned subsidiary of the Company has acquired a dialysis ....

Ref: NEPHROPLUS/SE/79 August 17, 2026 To To BSE Limited Na(cid:415)onal Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Lis(cid:415)ng Centre Through: NEAPS Subject: Disclosure under Regula(cid:415)on 30 and other applicable provisions of the Securi(cid:415)es and Exchange Board of India (Lis(cid:415)ng Obliga(cid:415)ons and Disclosure Requirements) Regula(cid:415)ons, 2015 (“SEBI Lis(cid:415)ng Regula(cid:415)ons”) Dear Sir/Madam, Pursuant to Regula(cid:415)on 30 of the SEBI Lis(cid:415)ng Regula(cid:415)ons and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Master Circular”), we hereby inform that Nephrocare Health Care Services, Philippines Inc., an overseas step-down wholly-owned subsidiary of Nephrocare Health Services Limited (“the Company”), has entered into an Asset Transfer Agreement (“ATA”) dated August 14, 2026 and has been executed on August 17, 2026 with Assump(cid:415)on Dialysis Center for the acquisi(cid:415)on of iden(cid:415)fied assets rela(cid:415)ng to a dialysis center located at Daang Maharlika, Brgy. Bunga, Abuyog, Leyte, Philippines, for a total considera(cid:415)on of PhP 75,000,000 (Philippine Pesos Seventy-Five Million Only), subject to the terms and condi(cid:415)ons set out therein. The details as required under Regula(cid:415)on 30 of the SEBI Lis(cid:415)ng Regula(cid:415)ons read with the aforesaid SEBI Master Circular are enclosed herewith as Annexure I. The aforesaid informa(cid:415)on is also being made available on the Company’s website at www.nephroplus.com. For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary & Head Legal ICSI M. No. F9895 ANNEXURE I Sr. Particulars Description 1. Name(s) of parties with whom the Nephrocare Health Care Services, agreement is entered Philippines Inc. (an overseas step-down wholly-owned subsidiary of the Company) (“Purchaser”) and Assumption Dialysis Center (“Seller”) 2. Purpose of entering into the Acquisition of the dialysis center assets agreement pursuant to the Asset Transfer Agreement (the “Transaction”), in accordance with and subject to the terms and conditions stipulated therein. 3. Size of agreement PhP 75,000,000.00 (Philippine Pesos Seventy-Five Million Pesos Only) 4. Shareholding, if any, in the entity Not Applicable with whom the agreement is executed 5. Significant terms of the There are no special rights as per the agreement (in brief) special rights agreements. like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.; 6. Whether, the said parties are Purchaser is an overseas step-down related to promoter/promoter wholly owned subsidiary of the Company. group/ group companies in any manner. If yes, nature of Seller is not related. relationship; 7. Whether the transaction would fall No within related party transactions? If yes, whether the same is done at “arm’s length” 8. In case of issuance of shares to Not applicable the parties, details of issue price, class of shares issued; 9. In case of loan agreements, details Not Applicable of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis; 10. Any other disclosures related to Not Applicable such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc. 11. In case of termination or Not Applicable amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a. Name of parties to the agreement; b. Nature of the agreement; c. Date of execution of the agreement; d. Details of amendment and impact thereof or reasons of termination and impact thereof.